NasdaqGS:SRPTBiotechs
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story
Earlier this week, Sarepta Therapeutics reported three-year topline results from its Phase 3 EMBARK trial showing ELEVIDYS produced statistically significant, durable improvements in motor function for ambulatory children with Duchenne muscular dystrophy, with no new safety signals observed.
A key insight from EMBARK is that ELEVIDYS-treated patients maintained motor abilities above baseline while comparable untreated patients followed the expected age-related decline, underscoring a...